$ATOS
ATOSSA THERAPEUTICS, INC.

2015 Q2 Form 10-Q Financial Statement

#000114420415030135 Filed on May 13, 2015

View on sec.gov

Income Statement

Concept 2015 Q2 2015 Q1 2014 Q4
Revenue $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
Cost Of Revenue $0.00 $0.00 $0.00
YoY Change -100.0%
Gross Profit $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
Gross Profit Margin
Selling, General & Admin $2.797M $2.707M $1.720M
YoY Change 4.15% 34.5% -23.56%
% of Gross Profit
Research & Development $373.5K $565.8K -$750.0K
YoY Change -26.88% 33.92% -302.7%
% of Gross Profit
Depreciation & Amortization $90.00K $64.25K $180.0K
YoY Change 353.08% -48.64% 50.0%
% of Gross Profit
Operating Expenses $3.171M $3.273M $980.0K
YoY Change -0.81% 34.4% -62.74%
Operating Profit -$3.171M -$3.273M -$980.0K
YoY Change -0.5% 35.74% -62.45%
Interest Expense $50.00K $1.784K $0.00
YoY Change 3365.0% 138.18%
% of Operating Profit
Other Income/Expense, Net $48.66K -$1.415K
YoY Change -3472.07%
Pretax Income -$3.122M -$3.274M -$3.330M
YoY Change -2.07% 35.77% 20.65%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$3.145M -$3.335M -$5.810M
YoY Change -1.34% 38.31% 110.51%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$21.00M -$23.86M -$41.50M
COMMON SHARES
Basic Shares Outstanding 27.22M shares 25.40M shares 24.56M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q2 2015 Q1 2014 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $11.40M $9.700M $8.500M
YoY Change -20.28% -41.57% 34.92%
Cash & Equivalents $11.40M $9.728M $8.501M
Short-Term Investments
Other Short-Term Assets $200.0K $300.0K $0.00
YoY Change -33.33% -70.0% -100.0%
Inventory $100.0K $94.63K $9.276K
Prepaid Expenses $263.8K $194.0K
Receivables $2.000M $1.280M $298.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $13.80M $11.37M $9.086M
YoY Change -6.12% -35.78% 34.37%
LONG-TERM ASSETS
Property, Plant & Equipment $400.0K $381.6K $136.7K
YoY Change 213.13% 193.66% -16.21%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $600.0K $176.6K $48.19K
YoY Change 0.0% -96.12% 32.23%
Total Long-Term Assets $2.800M $2.436M $2.678M
YoY Change -45.3% -47.98% -48.96%
TOTAL ASSETS
Total Short-Term Assets $13.80M $11.37M $9.086M
Total Long-Term Assets $2.800M $2.436M $2.678M
Total Assets $16.60M $13.80M $11.76M
YoY Change -16.24% -38.33% -2.04%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $600.0K $966.2K $513.0K
YoY Change -24.07% 106.75%
Accrued Expenses $2.700M $1.118M $254.1K
YoY Change 1091.31% 24.21% -13.95%
Deferred Revenue
YoY Change
Short-Term Debt $100.0K $100.0K $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.400M $3.487M $2.214M
YoY Change 117.46% 222.22% 57.98%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $3.400M $3.487M $2.214M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $3.400M $3.519M $2.266M
YoY Change 112.5% 219.91% 61.0%
SHAREHOLDERS EQUITY
Retained Earnings -$38.51M -$35.17M
YoY Change 67.96% 71.44%
Common Stock $27.22K $24.56K
YoY Change 11.41% 32.25%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $13.10M $10.28M $9.498M
YoY Change
Total Liabilities & Shareholders Equity $16.60M $13.80M $11.76M
YoY Change -16.24% -38.33% -2.04%

Cashflow Statement

Concept 2015 Q2 2015 Q1 2014 Q4
OPERATING ACTIVITIES
Net Income -$3.145M -$3.335M -$5.810M
YoY Change -1.34% 38.31% 110.51%
Depreciation, Depletion And Amortization $90.00K $64.25K $180.0K
YoY Change 353.08% -48.64% 50.0%
Cash From Operating Activities -$3.520M -$2.999M -$2.720M
YoY Change 55.75% 15.33% 2.64%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K -$70.00K -$50.00K
YoY Change -88.89% -30.0% -44.44%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$10.00K -$66.04K -$50.00K
YoY Change -88.89% -33.97% -44.44%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $4.292M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.210M 4.290M -100.0K
YoY Change 10320.0% -66.9% -107.19%
NET CHANGE
Cash From Operating Activities -3.520M -$2.999M -2.720M
Cash From Investing Activities -10.00K -$66.04K -50.00K
Cash From Financing Activities 5.210M 4.290M -100.0K
Net Change In Cash 1.680M -$3.065M -2.870M
YoY Change -173.04% -129.87% 112.59%
FREE CASH FLOW
Cash From Operating Activities -$3.520M -$2.999M -$2.720M
Capital Expenditures -$10.00K -$70.00K -$50.00K
Free Cash Flow -$3.510M -$2.929M -$2.670M
YoY Change 61.75% 17.15% 4.3%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q1 dei Entity Registrant Name
EntityRegistrantName
ATOSSA GENETICS INC
CY2015Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001488039
CY2015Q1 us-gaap Inventory Net
InventoryNet
94628 USD
CY2015Q1 dei Trading Symbol
TradingSymbol
ATOS
CY2015Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
263763 USD
CY2015Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2015Q1 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2015Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
27217257 shares
CY2015Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1877755 USD
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9728369 USD
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8500718 USD
CY2015Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1280209 USD
CY2014Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
297958 USD
CY2014Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
247207 USD
CY2014Q4 us-gaap Inventory Net
InventoryNet
39788 USD
CY2015Q1 us-gaap Assets Current
AssetsCurrent
11366969 USD
CY2014Q4 us-gaap Assets Current
AssetsCurrent
9085671 USD
CY2015Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
381590 USD
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
357532 USD
CY2014Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1920645 USD
CY2015Q1 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
0 USD
CY2014Q4 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
351961 USD
CY2015Q1 us-gaap Assets
Assets
13802865 USD
CY2014Q4 us-gaap Assets
Assets
11764002 USD
CY2015Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
966208 USD
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
594357 USD
CY2015Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1117932 USD
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
444861 USD
CY2015Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1279528 USD
CY2014Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1056705 USD
CY2015Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
42914 USD
CY2014Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
42228 USD
CY2015Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.70
CY2015Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-38509831 USD
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-35174540 USD
CY2015Q1 us-gaap Stockholders Equity
StockholdersEquity
10283852 USD
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
9498127 USD
CY2015Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13802865 USD
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11764002 USD
CY2015Q1 us-gaap Common Stock Value
CommonStockValue
27217 USD
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
24564 USD
CY2015Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
48766466 USD
CY2014Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
44648103 USD
CY2015Q1 us-gaap Liabilities Current
LiabilitiesCurrent
3486556 USD
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2214176 USD
CY2015Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2014Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7022201 shares
CY2015Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> <b><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Use of Estimates:</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> <b>&#160;</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2015Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2015Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27217257 shares
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24564058 shares
CY2015Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27217257 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24564058 shares
CY2015Q1 us-gaap Prepaid Advertising
PrepaidAdvertising
5995 USD
CY2014Q4 us-gaap Prepaid Advertising
PrepaidAdvertising
50000 USD
CY2015Q1 us-gaap Supplies
Supplies
6804 USD
CY2014Q4 us-gaap Supplies
Supplies
14976 USD
CY2015Q1 us-gaap Prepaid Insurance
PrepaidInsurance
103649 USD
CY2014Q4 us-gaap Prepaid Insurance
PrepaidInsurance
87633 USD
CY2015Q1 us-gaap Deposit Assets
DepositAssets
25000 USD
CY2014Q4 us-gaap Deposit Assets
DepositAssets
25000 USD
CY2015Q1 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
81002 USD
CY2014Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
31330 USD
CY2015Q1 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
574848 USD
CY2014Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
522813 USD
CY2015Q1 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
96491 USD
CY2014Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
93665 USD
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
258946 USD
CY2015Q1 us-gaap Depreciation
Depreciation
30802 USD
CY2014Q4 us-gaap Finite Lived Patents Gross
FiniteLivedPatentsGross
1630000 USD
CY2014Q4 us-gaap Finite Lived License Agreements Gross
FiniteLivedLicenseAgreementsGross
200000 USD
CY2014Q4 us-gaap Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
203038 USD
CY2014Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
112393 USD
CY2015Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
163126 USD
CY2015Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
228529 USD
CY2015Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
197168 USD
CY2015Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
169325 USD
CY2014Q1 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
0 USD
CY2015Q1 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
470 USD
CY2014Q1 us-gaap Sales Revenue Net
SalesRevenueNet
24124 USD
CY2015Q1 us-gaap Sales Revenue Net
SalesRevenueNet
1873268 USD
CY2015Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
169015 USD
CY2015Q1 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
950592 USD
CY2015Q1 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
896884 USD
CY2015Q1 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
157959 USD
CY2015Q1 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
224685 USD
CY2015Q1 atos Total Shares Authorized
TotalSharesAuthorized
85000000 shares
CY2015Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
6033426 shares
CY2014Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
15.00
CY2014Q2 atos Percentage Of Common Stock Outstanding
PercentageOfCommonStockOutstanding
0.020 pure
CY2014Q2 atos Entitled To Receive Worth Of Common Stock
EntitledToReceiveWorthOfCommonStock
30.00
CY2014Q1 us-gaap Cost Of Services
CostOfServices
0 USD
CY2015Q1 us-gaap Cost Of Services
CostOfServices
1206312 USD
CY2014Q1 us-gaap Cost Of Goods Sold
CostOfGoodsSold
0 USD
CY2015Q1 us-gaap Cost Of Goods Sold
CostOfGoodsSold
1642 USD
CY2014Q1 us-gaap Cost Of Revenue
CostOfRevenue
0 USD
CY2015Q1 us-gaap Cost Of Revenue
CostOfRevenue
1207954 USD
CY2014Q1 us-gaap Gross Profit
GrossProfit
24124 USD
CY2015Q1 us-gaap Gross Profit
GrossProfit
665314 USD
CY2014Q1 us-gaap Selling Expense
SellingExpense
237838 USD
CY2015Q1 us-gaap Selling Expense
SellingExpense
546854 USD
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
422503 USD
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
797225 USD
CY2014Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1774708 USD
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2605111 USD
CY2014Q1 us-gaap Operating Expenses
OperatingExpenses
2435049 USD
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
3949190 USD
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2410925 USD
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3283876 USD
CY2014Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
143 USD
CY2015Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
279 USD
CY2014Q1 us-gaap Interest Expense
InterestExpense
749 USD
CY2015Q1 us-gaap Interest Expense
InterestExpense
1784 USD
CY2014Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-2411531 USD
CY2015Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-3335291 USD
CY2014Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2015Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-2411531 USD
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-3335291 USD
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.13
CY2015Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10387844 shares
CY2015Q1 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 USD
CY2015Q1 us-gaap Cash Uninsured Amount
CashUninsuredAmount
9478369 USD
CY2014Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
8250718 USD
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3675634 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
768322 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
89538 shares
CY2015Q1 atos Stock Issued During Period Shares Stock Options Exercised1
StockIssuedDuringPeriodSharesStockOptionsExercised1
0 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4354418 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1494728 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
3967136 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.86
CY2015Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.56
CY2015Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.71
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.21
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y2M12D
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y2M23D
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y1M2D
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
344000 USD
CY2015Q1 atos Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue
51750 USD
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0 USD
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
884650 USD
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
140282 USD
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
797960 USD
CY2014Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
230181 USD
CY2015Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
180628 USD
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P3Y1M28D
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
2859690 shares
CY2015Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2302162 USD
CY2015Q1 us-gaap Stock Issued During Period Value Issued For Cash
StockIssuedDuringPeriodValueIssuedForCash
4292349 USD
CY2015Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
351961 USD
CY2015Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
180628 USD
CY2014Q1 us-gaap Profit Loss
ProfitLoss
-2411531 USD
CY2015Q1 us-gaap Profit Loss
ProfitLoss
-3335291 USD
CY2014Q1 us-gaap Share Based Compensation
ShareBasedCompensation
230181 USD
CY2015Q1 us-gaap Share Based Compensation
ShareBasedCompensation
180628 USD
CY2014Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
125097 USD
CY2015Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
84867 USD
CY2014Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
27860 USD
CY2015Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
218482 USD
CY2014Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-19796 USD
CY2015Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1200733 USD
CY2014Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
0 USD
CY2015Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
54840 USD
CY2014Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
245178 USD
CY2015Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
16556 USD
CY2014Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
42944 USD
CY2015Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
371851 USD
CY2014Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-150504 USD
CY2015Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
222823 USD
CY2014Q1 atos Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
-13134 USD
CY2015Q1 atos Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
4744 USD
CY2014Q4 atos Prepaid Maintenance And Support Service Fee
PrepaidMaintenanceAndSupportServiceFee
38268 USD
CY2014Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-75905 USD
CY2015Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
653034 USD
CY2014Q1 atos Increase Decrease In Product Recall Liabilities
IncreaseDecreaseInProductRecallLiabilities
-115292 USD
CY2015Q1 atos Increase Decrease In Product Recall Liabilities
IncreaseDecreaseInProductRecallLiabilities
0 USD
CY2014Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-13460 USD
CY2015Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
687 USD
CY2014Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
2483 USD
CY2015Q1 atos Prepaid Maintenance And Support Service Fee
PrepaidMaintenanceAndSupportServiceFee
41313 USD
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2603989 USD
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2998663 USD
CY2014Q1 us-gaap Payments To Acquire Furniture And Fixtures
PaymentsToAcquireFurnitureAndFixtures
2966 USD
CY2015Q1 us-gaap Payments To Acquire Furniture And Fixtures
PaymentsToAcquireFurnitureAndFixtures
54860 USD
CY2014Q1 us-gaap Payments To Acquire Software
PaymentsToAcquireSoftware
100000 USD
CY2015Q1 us-gaap Payments To Acquire Software
PaymentsToAcquireSoftware
11175 USD
CY2014Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-102966 USD
CY2015Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-66035 USD
CY2014Q1 atos Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
12955745 USD
CY2015Q1 atos Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
4292349 USD
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
12955745 USD
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
4292349 USD
CY2014Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
10248790 USD
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1227651 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6342161 USD
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16590951 USD
CY2014Q1 us-gaap Interest Paid
InterestPaid
749 USD
CY2015Q1 us-gaap Interest Paid
InterestPaid
1784 USD
CY2015Q1 us-gaap Nature Of Operations
NatureOfOperations
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b>NOTE 1: NATURE OF OPERATIONS</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <strong>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> Atossa Genetics Inc. (the &#8220;Company&#8221;) was incorporated on April 30, 2009 in the State of Delaware. The Company&#8217;s operations began in December 2008 with the negotiations for the acquisition of the Mammary Aspirate Specimen Cytology Test System, or the MASCT System, patent rights and assignments and the FDA clearance for marketing, which acquisition was completed in January 2009. The Company was formed to develop and market the MASCT System, which is a medical device that collects specimens of nipple aspirate fluid (NAF).&#160;The Company&#8217;s fiscal year ends on December 31st.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In December 2011, the Company established The National Reference Laboratory for Breast Health, Inc., or NRLBH, as a wholly-owned subsidiary which performs the Company&#8217;s NAF cytology test on NAF specimens including those collected with the MASCT System. The NRLBH is certified by College of American Pathologists (CAP) and by Clinical Laboratory Improvement Amendments (CLIA). The current version of the MASCT System is called the ForeCYTE Breast Aspirator. The NRLBH is providing other test services, <font style="BACKGROUND-COLOR: transparent">including the pharmacogenomics test which provides physicians with genetic information that can be used to guide therapeutic decisions and may mitigate the incidence of costly adverse drug reactions and improve efficiencies.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Since its inception, the Company has been dependent upon the receipt of capital investment to fund its continuing activities. In addition to the normal risks associated with a new business venture, there can be no assurance that the Company&#8217;s business plan will be successfully executed. The Company&#8217;s ability to execute its business plan will depend on its ability to obtain additional financing and achieve a profitable level of operations. There can be no assurance that sufficient financing will be obtained. Further, the Company cannot give any assurance that it will generate substantial revenue or that its business operations will prove to be profitable.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
176551 USD
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
48193 USD
CY2015Q1 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
79974 USD
CY2014Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
76025 USD
CY2015Q1 us-gaap Liabilities
Liabilities
3519013 USD
CY2014Q4 us-gaap Liabilities
Liabilities
2265875 USD
CY2015Q1 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
25230 USD
CY2014Q4 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
49216 USD
CY2015Q1 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
7227 USD
CY2015Q1 atos Working Capital
WorkingCapital
7900000 USD
CY2015Q1 atos Amortization Of Capital Lease Equipment Straight Line Basis
AmortizationOfCapitalLeaseEquipmentStraightLineBasis
P5Y
CY2015Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2014Q1 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
230181 USD
CY2015Q1 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
180628 USD
CY2015Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
671339 USD
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
616478 USD
CY2015Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
2044212 USD
CY2014Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
2033038 USD
CY2014Q1 us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
24124 USD
CY2015Q1 us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
1872798 USD
CY2014Q3 us-gaap Other Commitments Description
OtherCommitmentsDescription
On September 1, 2014, the NRLBH entered into a three year agreement with TME Research LLC (TME) which requires TME to provide to the NRLBH 100 tissue specimens in connection with the development of the NextCYTE test. Fees payable to TME under the agreement includes $99,600 up front, $31,500 upon supplying the first 25 specimens and $31,500 at the time of final delivery of all specimens. The agreement is terminable with 60 days prior written notice or immediately upon a material breach.
CY2015Q1 atos Noncash Reclass Of Prepaid License Fees
NoncashReclassOfPrepaidLicenseFees
USD
CY2014Q1 atos Amortization Of Commitment Shares Issued For Shares Distributed For Capital Contribution
AmortizationOfCommitmentSharesIssuedForSharesDistributedForCapitalContribution
75000 USD
CY2015Q1 atos Amortization Of Commitment Shares Issued For Shares Distributed For Capital Contribution
AmortizationOfCommitmentSharesIssuedForSharesDistributedForCapitalContribution
351961 USD
CY2015Q1 us-gaap Accrued Sales Commission Current
AccruedSalesCommissionCurrent
924825 USD
CY2014Q4 us-gaap Accrued Sales Commission Current
AccruedSalesCommissionCurrent
174398 USD
CY2015Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
138144 USD
CY2014Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
254126 USD
CY2015Q1 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
54963 USD
CY2014Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
16337 USD
CY2015Q1 us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
-49910 USD
CY2014Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
24863 USD
CY2015Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
128359 USD

Files In Submission

Name View Source Status
0001144204-15-030135-index-headers.html Edgar Link pending
0001144204-15-030135-index.html Edgar Link pending
0001144204-15-030135.txt Edgar Link pending
0001144204-15-030135-xbrl.zip Edgar Link pending
atos-20150331.xml Edgar Link completed
atos-20150331.xsd Edgar Link pending
atos-20150331_cal.xml Edgar Link unprocessable
atos-20150331_def.xml Edgar Link unprocessable
atos-20150331_lab.xml Edgar Link unprocessable
atos-20150331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v408515_10q.htm Edgar Link pending
v408515_ex21.htm Edgar Link pending
v408515_ex31-1.htm Edgar Link pending
v408515_ex31-2.htm Edgar Link pending
v408515_ex32-1.htm Edgar Link pending
v408515_ex32-2.htm Edgar Link pending